Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased cardiovascular risk, a daily orforglipron pill had cardiovascular safety comparable to daily insulin glargine injections while providing greater improvements in weight and…
New research from the European Association for the Study of Diabetes (EASD) meeting in Milan reveals that a daily oral medication called orforglipron may serve as a feasible alternative to daily insulin injections for certain diabetes patients with cardiovascular risk. Conducted by Eli Lilly, the study found orforglipron to be non-inferior to insulin glargine in preventing major cardiovascular events, while also delivering greater reductions in weight and better blood sugar control.
However, gastrointestinal side effects were more common with orforglipron, leading to higher discontinuation rates.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
